Skip to main content
. 2012 Apr 16;7(4):e35436. doi: 10.1371/journal.pone.0035436

Figure 2. Sub-optimal dosing of NVP-AUY922 delays tumor growth and increases time to surrogate endpoint in vivo in conjunction with ionising radiation.

Figure 2

Radiosensitization due to NVP-AUY922 was assessed in vivo in a human xenograft model. HN3 cells were allowed to achieve a tumor volume of 5–8 mm after implantation in the right flank and evenly distributed into four treatment groups with matching average tumor volumes; vehicle only control (n = 8); NVP-AUY922, four doses of 10 mg/kg each (n = 9); 9 Gy ionising radiation fractionated in three doses of 3 Gy (n = 9); NVP-AUY922 and ionising radiation (n = 8). (A) Scheduling of four rounds of 10 mg/kg NVP-AUY922 or vehicle only was administered by interperitonal injection, followed by fractioned tumor-targeted radiotherapy of 3 Gy each to a cumulative total of 9 Gy on days one to three. Tumor sizes were measured every 3–4 days with resulting percentage baseline tumor volume (B) and percentage surrogate endpoint (C) shown. Data represents ± SEM. Mantel-Cox log-rank test carried out for statistical analysis of surrogate endpoint data (p = 0.0002).